{"transactions":[{"id":2373917,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2022-02-25T00:03:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":50000,"derivative":{"exercise_price":1.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-005444","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222005444/ownership.xml","form_type":"4"}},{"id":2643507,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2021-07-02T22:07:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":329250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":329250,"derivative":{"exercise_price":2.59,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":329250},"source":{"system":"sec-edgar","filing":"0001192482-21-000612","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000612/edgar.xml","form_type":"4"}},{"id":2643506,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2021-07-02T22:07:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":19755,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":19755,"derivative":{"exercise_price":2.59,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":19755},"source":{"system":"sec-edgar","filing":"0001192482-21-000612","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000612/edgar.xml","form_type":"4"}}]}